Despite the declining overall trend of ASIR, ASDR and age-standardized DALYs at the expense of high SDI quintiles, the CML burden remains stable due to the growing population in developing countries and the aging population in developed countries. Management of patients with primary diagnosed CML, with high risk factors, should include enhanced surveillance for SARS-CoV-2 infection. Diagnostics management of patients with CML includes morphological, cytogenetic and molecular-genetic investigations of the peripheral blood and bone marrow regardless of the phase of clinical evolution, with FISH and RT-PCR as proving resolutive modalities.
Chronic myeloid leukemia (CML) comprises 15-20% of all leukemia cases in adults, being the most common chronic myeloproliferative neoplasm, with the patients’ immunocompromised status in the advanced phases. The international periodical literature stipulates the increased susceptibility of patients with malignant tumors to SARS-CoV-2 infection, but the contagion risk is not determined in regard to the histological type of hematologic malignancies. The aim of the study was the comparative evaluation of the current epidemiological patterns and the contemporary diagnostics output in CML, axed on the optimization of tactics of diagnosis management in the context of the pandemic with COVID-19 infection.